Meeting
2023 ASCO Annual Meeting
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.
Authors
Jonathan Bender
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Jonathan Bender , Sudarshawn Damodharan , Amy Moskop , Keri Toner , Anant Vatsayan , Christian Capitini , Christina Baggott , Deborah E. Schiff , Emmanuel Katsanis , Sunil S. Raikar , Julie-An M. Talano , Liora M. Schultz , Lauren Pommert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10031)
DOI
10.1200/JCO.2023.41.16_suppl.10031
Abstract #
10031
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.
First Author: John Lin
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody
Poster
2021 ASCO Annual Meeting
Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
First Author: Stephen J. Schuster
Poster
2021 ASCO Annual Meeting
Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).
First Author: Nancy L. Bartlett